Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients

The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle as a vaccine and demonstrate induction of ro...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2020-04
Main Authors: Mckay, Paul F, Hu, Kai, Blakney, Anna K, Samnuan, Karnyart, Bouton, Clement R, Rogers, Paul, Polra, Krunal, Lin, Paulo J C, Barbosa, Christopher, Tam, Ying, Shattock, Robin J
Format: Article
Language:English
Subjects:
Coronaviruses
COVID-19
Immunogenicity
Immunoglobulin G
Nanoparticles
Pandemics
Ribonucleic acid
RNA
Severe acute respiratory syndrome coronavirus 2
Spike protein
Vaccines
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle as a vaccine and demonstrate induction of robust neutralization of a pseudo-virus, proportional to quantity of specific IgG and of higher quantities than recovered COVID-19 patients. These data provide insight into the vaccine design and evaluation of immunogenicity to enable rapid translation to the clinic. Competing Interest Statement The authors have declared no competing interest.
DOI:10.1101/2020.04.22.055608